We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Corcept (CORT) Begins Adrenal Cancer Study on Relacorilant
Read MoreHide Full Article
Corcept Therapeutics Incorporated (CORT - Free Report) announced that it has enrolled the first patient in the phase Ib study evaluating relacorilant in combination with Merck’s (MRK - Free Report) PD-1 checkpoint inhibitor, Keytruda, for the treatment of patients suffering from adrenal cancer with cortisol excess.
Corcept plans to enroll 20 patients with metastatic/unresectable adrenal cancer with cortisol excess in the above-mentioned study across various sites in the United States.
Shares of Corcept have fallen 1.4% so far this year against the industry’s increase of 1.9%.
We remind investors that Corcept’s lead candidate, relacorilant, is being evaluated in the phase III GRACE study to treat Cushing’s syndrome. The company plans to submit a new drug application for relacorilant in the second quarter of 2023. Meanwhile, enrollment is underway in the phase III study of GRADIENT on relacorilant in patients whose Cushing’s syndrome is caused by adrenal adenoma at sites across the United States, Europe and Israel.
Meanwhile, Corcept has completed enrollment in a phase II study on relacorilant in combination with Bristol Myers’ (BMY - Free Report) Abraxane for the treatment of metastatic ovarian cancer. The combo of relacorilant plus Abraxane is also being evaluated for addressing patients with metastatic pancreatic cancer. Preliminary results from both studies are expected in the first half of 2021.
Apart from relacorilant, Corcept’s other pipeline candidates include exicorilant and miricorilant, which are also progressing well.
The company is conducting an open-label dose-finding study on exicorilant in combination with Pfizer’s (PFE - Free Report) Xtandi for treating patients with metastatic castration-resistant prostate cancer.
Corcept is enrolling patients in a phase II GRATITUDE study on miricorilant for addressing the reversal of APIWG. In September 2020, the company enrolled the first patient in the phase II GRATITUDE 2 study of miricorilant to reverse the long-standing APIWG. In the fourth quarter of 2020, the company initiated a phase II study evaluating miricorilant as a potential treatment for NASH, a serious liver disorder.
If successfully developed and upon potential approval, any of the aforementioned candidates should drive growth for Corcept in the days ahead.
In addition to the stocks discussed above, would you like to know about our 10 best buy-and-hold tickers for the entirety of 2021?
Last year's 2020Zacks Top 10 Stocks portfolio returned gains as high as +386.8%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Image: Bigstock
Corcept (CORT) Begins Adrenal Cancer Study on Relacorilant
Corcept Therapeutics Incorporated (CORT - Free Report) announced that it has enrolled the first patient in the phase Ib study evaluating relacorilant in combination with Merck’s (MRK - Free Report) PD-1 checkpoint inhibitor, Keytruda, for the treatment of patients suffering from adrenal cancer with cortisol excess.
Corcept plans to enroll 20 patients with metastatic/unresectable adrenal cancer with cortisol excess in the above-mentioned study across various sites in the United States.
Shares of Corcept have fallen 1.4% so far this year against the industry’s increase of 1.9%.
We remind investors that Corcept’s lead candidate, relacorilant, is being evaluated in the phase III GRACE study to treat Cushing’s syndrome. The company plans to submit a new drug application for relacorilant in the second quarter of 2023. Meanwhile, enrollment is underway in the phase III study of GRADIENT on relacorilant in patients whose Cushing’s syndrome is caused by adrenal adenoma at sites across the United States, Europe and Israel.
Meanwhile, Corcept has completed enrollment in a phase II study on relacorilant in combination with Bristol Myers’ (BMY - Free Report) Abraxane for the treatment of metastatic ovarian cancer. The combo of relacorilant plus Abraxane is also being evaluated for addressing patients with metastatic pancreatic cancer. Preliminary results from both studies are expected in the first half of 2021.
Apart from relacorilant, Corcept’s other pipeline candidates include exicorilant and miricorilant, which are also progressing well.
The company is conducting an open-label dose-finding study on exicorilant in combination with Pfizer’s (PFE - Free Report) Xtandi for treating patients with metastatic castration-resistant prostate cancer.
Corcept is enrolling patients in a phase II GRATITUDE study on miricorilant for addressing the reversal of APIWG. In September 2020, the company enrolled the first patient in the phase II GRATITUDE 2 study of miricorilant to reverse the long-standing APIWG. In the fourth quarter of 2020, the company initiated a phase II study evaluating miricorilant as a potential treatment for NASH, a serious liver disorder.
If successfully developed and upon potential approval, any of the aforementioned candidates should drive growth for Corcept in the days ahead.
Zacks Rank
Corcept currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks Top 10 Stocks for 2021
In addition to the stocks discussed above, would you like to know about our 10 best buy-and-hold tickers for the entirety of 2021?
Last year's 2020Zacks Top 10 Stocks portfolio returned gains as high as +386.8%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
AccessZacks Top 10 Stocks for 2021 today >>